By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

Lonza said on Thursday it plans to exit the capsules and health ingredients business, as the Swiss contract drugmaker faced a ...

The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

Lonza forecasts 2025 CER sales growth of nearly 20%, supported by organic growth and acquisitions, with CORE EBITDA margins nearing 30%. The streamlined organizational model, operational by Q2 2025, ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

The Switzerland market exhibited some weakness early on in the session on Thursday, and despite a smart recovery, failed to sustain ...

A $1 million fence designed to protect one of the world’s most important wildlife populations is once again falling down.

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...